July 30, 2020 -- Inovio released results of a nonhuman primate study for its COVID-19 DNA vaccine, INO-4800. The vaccine protected the animals 13 weeks after vaccinations and mediated T- and B-cell immune responses, according to the firm.
The results, published on bioRxiv, demonstrated that INO-4800 reduced viral load in the lungs and nasal passages of macaques that received two doses of INO-4800 (one mg) four weeks apart followed by live virus challenge 13 weeks after the second dose.
The vaccinated macaques demonstrated seroconversion after a single dose, with neutralizing antibodies and T cells found in their blood more than four months after the initial dose. Moreover, the levels of antibodies were similar to or greater than those who have recovered from COVID-19. The study showed that the vaccine induced acute and memory T- and B-cell responses, including neutralizing antibodies against the early virus strain as well as the now dominant G614 variant.
The company anticipates beginning phase II/III efficacy trials this summer. A separate nonhuman primate study evaluating the durability of INO-4800 at 12 months postvaccination is currently underway and is supported by the federal government's Operation Warp Speed to accelerate development of a vaccine for SARS-CoV-2.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
